Comparative efficacy of THR-β agonists, FGF-21 analogues, GLP-1R agonists, GLP-1-based polyagonists, and Pan-PPAR agonists for MASLD: A systematic review and network meta-analysis

• Published in: Metabolism, clinical and experimental Vol. 161; p. 156043
• Main Authors: Lin, Ru-Tao, Sun, Qin-Mei, Xin, Xin, Ng, Cheng Han, Valenti, Luca, Hu, Yi-Yang, Zheng, Ming-Hua, Feng, Qin
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.12.2024
• Subjects: Fibroblast growth factor 21; Glucagon-like peptide-1; Meta-analysis; Metabolic dysfunction-associated steatotic liver disease; Pan-peroxisome proliferator-activated receptor; Thyroid hormone receptor beta; MRE; CK18/M30; THR-β; Fibroblast growth factor 21; Metabolic dysfunction-associated steatotic liver disease; Thyroid hormone receptor beta; HDL-cholesterol; Pan-peroxisome proliferator-activated receptor; HFF; ALT; MASH; Pro-c3; MASL; LDL-cholesterol; 95 % CI; DBP; MD; FGF-21; HbA1c; NASH CRN; BMI; SBP; AST; GLP-1; OR; SUCRA; GCG; MASLD; Pan-PPAR; GIP; Meta-analysis; Glucagon-like peptide-1; GGT; MRI-PDFF; FIB-4; ELF; GLP-1R
• ISSN: 0026-0495; 1532-8600; 1532-8600
• DOI: 10.1016/j.metabol.2024.156043

To compare the efficacy of thyroid hormone receptor beta (THR-β) agonists, fibroblast growth factor 21 (FGF-21) analogues, glucagon-like peptide-1 receptor agonists (GLP-1RAs), GLP-1-based polyagonists, and pan-peroxisome proliferator-activated receptor (Pan-PPAR) agonists in the treatment of metabolic dysfunction-associated steatotic liver disease (MASLD). A database search for relevant randomized double-blind controlled trials published until July 11, 2024, was conducted. Primary outcomes were the relative change in hepatic fat fraction (HFF) and liver stiffness assessed non-invasively by magnetic resonance imaging proton density fat fraction and elastography. Secondary outcomes included histology, liver injury index, lipid profile, glucose metabolism, blood pressure, and body weight. Twenty-seven trials (5357 patients with MASLD) were identified. For HFF reduction, GLP-1-based polyagonists were most potentially effective (mean difference [MD] −51.47; 95 % confidence interval [CI]: −68.25 to −34.68; surface under the cumulative ranking curve [SUCRA] 84.9) vs. placebo, followed by FGF-21 analogues (MD −47.08; 95 % CI: −58.83 to −35.34; SUCRA 75.5), GLP-1R agonists (MD −37.36; 95 % CI: −69.52 to −5.21; SUCRA 52.3) and THR-β agonists (MD −33.20; 95 % CI: −43.90 to −22.51; SUCRA 36.9). For liver stiffness, FGF-21 analogues were most potentially effective (MD −9.65; 95 % CI: −19.28 to −0.01; SUCRA 82.2) vs. placebo, followed by THR-β agonists (MD −5.79; 95 % CI: −9.50 to −2.09; SUCRA 58.2), and GLP-1RAs (MD −5.58; 95 % CI: −15.02 to 3.86; SUCRA 54.7). For fibrosis improvement in histology, GLP-1-based polyagonists were most potentially effective, followed by FGF-21 analogues, THR-β agonists, Pan-PPAR agonists, and GLP-1R agonists; For MASH resolution in histology, GLP-1-based polyagonists were most potentially effective, followed by THR-β agonists, GLP-1R agonists, FGF-21 analogues, and Pan-PPAR agonists. THR-β agonists are well-balanced in liver steatosis and fibrosis, and excel at improving lipid profiles; FGF-21 analogues are effective at improving steatosis and particularly exhibit strong antifibrotic abilities. GLP-1R agonists showed significant benefits in improving liver steatosis, glucose metabolism, and body weight. GLP-1-based polyagonists have demonstrated the most potential efficacy overall in terms of comprehensive curative effect. Pan-PPAR agonists showed distinct advantages in improving liver function and glucose metabolism. These results illustrate the relative superiority of the five classes of therapy in the treatment of MASLD and may serve as guidance for the development of combination therapies. •GLP-1-based polyagonists have the most potential efficacy overall in terms of comprehensive curative effect.•FGF-21 analogues are effective at improving steatosis and particularly exhibit strong antifibrotic abilities.•THR-β agonists are effective in reducing liver steatosis and fibrosis and excel at improving lipid profiles.•GLP-1R agonists showed significant benefits in improving liver steatosis, glucose metabolism, and body weight.•Pan-PPAR agonists showed distinct advantages in improving liver function and glucose metabolism.